Clara Health, Now a Part of M&B Sciences, Named Among California’s Most Innovative Clinical Trial Companies

Clara Health, Now a Part of M&B Sciences, Named Among California’s Most Innovative Clinical Trial Companies




Clara Health, Now a Part of M&B Sciences, Named Among California’s Most Innovative Clinical Trial Companies

SAN FRANCISCO–(BUSINESS WIRE)–Clara Health, now M&B Sciences, has been named among the top 35 most innovative clinical trial companies in the Bay Area by Best Startup California.

The directory tracks more than 300,000 companies in California and selected the finalists for their track record, executive leadership team, market share, innovation, and environment, social and governance (ESG) rating.

Clara Health has been a leader in patient recruitment and retention technology since 2015 and now provides a full range of services to support clinical trial teams, including protocol design and site selection. The Clara Health team shares M&B Sciences’ mission to democratize access to clinical trials to improve healthcare equity for everyone.

M&B Sciences, a fast-growing African-American-owned technology and research firm focused on the life sciences industry, acquired Clara Health in March and recently launched a new NeighborhoodTrials mobile app to make it easy for patients to participate in clinical trials close to home.

The acquisition expands M&B’s already robust technology platform and resources, which includes its proprietary provider database with over one million providers, furthering its commitment to accelerating patient recruitment, improving diversity in clinical research and ultimately improving healthcare outcomes for all. In addition to patient recruitment, the company provides patient concierge services, clinical trials site management, development of patient registries and regulatory support services.

What makes M&B Sciences unique is its ability to leverage its team’s expertise in surveillance epidemiology, data science, and spatial statistics to assess and understand burden of disease at the neighborhood level and then engage in active patient recruitment.

“We are honored to receive this recognition and excited about the opportunities ahead,” M&B Sciences CEO Dr. Eddilisa Martin said. “More than 80% of clinical trials experience delays because of difficulties with recruitment. We have the ability to help sponsors recruit participants up to eight times faster, which can make a significant impact when it comes to bringing life-saving treatments to the people who need them.”

About M&B Sciences Inc

Based in San Diego, California, M&B Sciences, Inc is a privately held technology and research firm focused on supporting pharmaceutical, biotech, medtech and healthcare organizations in the areas of patient recruitment, patient engagement, clinical trial operations, project management, large scale data analytics, post approval surveillance, and regulatory support. For more information, visit www.mbsciences.com.

Contacts

Eddilisa Martin, Pharm.D., M&B Sciences Owner & CEO

eddilisa.martin@mbsciences.com
Ph: 858-812-8735